PriceTargets.com logo

Arcus Biosciences - RCUS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $41.33
  • Forecasted Upside: 152.65%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$16.36 As of 03/23/2023 01:00 AM ET
▲ +0.4 (2.51%)

This chart shows the closing price for RCUS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arcus Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RCUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCUS

Analyst Price Target is $41.33
▲ +152.65% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Arcus Biosciences in the last 3 months. The average price target is $41.33, with a high forecast of $51.00 and a low forecast of $33.00. The average price target represents a 152.65% upside from the last price of $16.36.

This chart shows the closing price for RCUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Arcus Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/29/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2023

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2023MizuhoReiterated RatingBuy$51.00Low
3/9/2023CitigroupLower Target$42.00 ➝ $40.00Low
12/21/2022BarclaysLower TargetOverweight$60.00 ➝ $36.00Low
12/20/2022CitigroupBoost TargetBuy$37.00 ➝ $42.00Low
11/23/2022CitigroupLower TargetBuy$40.00 ➝ $37.00Low
11/18/2022Bank of AmericaInitiated CoverageNeutral$33.00Low
11/3/2022SVB LeerinkLower TargetOutperform$40.00 ➝ $38.00Low
10/11/2022Morgan StanleyInitiated CoverageOverweight$40.00Low
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
8/18/2022CitigroupLower Target$48.00 ➝ $40.00Low
8/4/2022Cantor FitzgeraldLower Target$62.00 ➝ $48.00Low
8/4/2022WedbushLower TargetOutperform$42.00 ➝ $36.00Low
8/4/2022SVB LeerinkLower TargetOutperform$66.00 ➝ $49.00Low
7/8/2022Truist FinancialLower TargetBuy$77.00 ➝ $50.00N/A
5/11/2022WedbushLower Target$67.00 ➝ $42.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
2/25/2022Truist FinancialBoost Target$70.00 ➝ $77.00High
1/13/2022The Goldman Sachs GroupLower Target$45.00 ➝ $43.00Medium
1/7/2022SVB LeerinkReiterated RatingOutperformMedium
11/19/2021WedbushBoost TargetOutperform$52.00 ➝ $67.00High
11/19/2021CitigroupBoost TargetBuy$42.00 ➝ $53.00High
11/19/2021BarclaysBoost TargetOverweight$48.00 ➝ $60.00High
11/18/2021SVB LeerinkBoost TargetOutperform$68.00 ➝ $100.00High
11/9/2021BarclaysBoost TargetPositive ➝ Overweight$45.00 ➝ $48.00High
11/9/2021MizuhoBoost TargetBuy$43.00 ➝ $51.00High
8/6/2021SVB LeerinkBoost TargetOutperform$63.00 ➝ $68.00High
7/14/2021SVB LeerinkSet TargetBuy$28.40High
6/24/2021SVB LeerinkBoost TargetPositive ➝ Outperform$53.00 ➝ $63.00High
2/25/2021SVB LeerinkLower TargetOutperform$54.00 ➝ $53.00Medium
2/25/2021BarclaysBoost TargetOverweight$40.00 ➝ $45.00Medium
2/25/2021MizuhoBoost TargetBuy$40.00 ➝ $43.00Medium
1/26/2021SVB LeerinkBoost TargetOutperform$41.00 ➝ $54.00High
1/20/2021BenchmarkBoost TargetBuy$32.00 ➝ $51.00High
1/19/2021Truist FinancialBoost Target$45.00 ➝ $70.00Low
1/19/2021WedbushBoost TargetOutperform$48.00 ➝ $55.00Low
1/13/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$39.00 ➝ $62.00Medium
11/24/2020Berenberg BankInitiated CoverageBuy$50.00 ➝ $50.00Medium
11/23/2020Evercore ISIInitiated CoverageOutperformHigh
11/6/2020SVB LeerinkLower TargetOutperform$44.00 ➝ $41.00Medium
8/10/2020WedbushReiterated RatingOutperformLow
8/10/2020SVB LeerinkBoost TargetOutperform$42.00 ➝ $44.00High
6/10/2020SunTrust BanksBoost TargetBuy$22.00 ➝ $45.00Low
6/2/2020CitigroupBoost Target$15.00 ➝ $41.00Low
5/29/2020SVB LeerinkReiterated RatingOutperform$21.00 ➝ $42.00High
5/27/2020WedbushBoost TargetOutperform$40.00 ➝ $48.00High
5/19/2020Cantor FitzgeraldReiterated RatingOverweightLow
5/14/2020MizuhoBoost TargetBuy$22.00 ➝ $40.00High
5/7/2020BarclaysReiterated RatingBuy$35.00High
5/6/2020WedbushBoost TargetOutperform$26.00 ➝ $40.00High
4/16/2020BTIG ResearchBoost Target$20.00 ➝ $34.00High
4/2/2020Cantor FitzgeraldInitiated CoverageOverweight$21.00High
4/1/2020SunTrust BanksBoost TargetBuy$20.00 ➝ $22.00High
3/4/2020BarclaysInitiated CoverageOverweight$24.00High
2/26/2020MizuhoReiterated RatingBuy$22.00Medium
12/18/2019MizuhoInitiated CoverageBuy$22.00High
11/12/2019SunTrust BanksInitiated CoverageBuy$20.00High
11/11/2019MizuhoReiterated RatingBuy$22.00Low
10/20/2019MizuhoReiterated RatingBuyMedium
9/26/2019MizuhoInitiated CoverageBuy$22.00High
6/5/2019CitigroupLower TargetBuy ➝ In-Line$25.00 ➝ $15.00Low
5/24/2019CitigroupReiterated RatingBuy ➝ Buy$25.00Low
5/3/2019SVB LeerinkReiterated RatingOutperformHigh
3/18/2019BTIG ResearchInitiated CoverageBuy$20.00Low
10/9/2018WedbushInitiated CoverageOutperform ➝ Outperform$22.00High
4/9/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$21.00High
4/9/2018CitigroupInitiated CoverageBuy ➝ Buy$18.00High
4/9/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$18.00High
(Data available from 3/23/2018 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/24/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2022
  • 4 very positive mentions
  • 7 positive mentions
  • 5 negative mentions
  • 6 very negative mentions
Mentions as of
12/23/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/22/2023
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/21/2023
  • 7 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2023

Current Sentiment

  • 7 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Arcus Biosciences logo
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Read More

Today's Range

Now: $16.36
Low: $16.00
High: $16.59

50 Day Range

MA: $19.42
Low: $15.96
High: $23.15

52 Week Range

Now: $16.36
Low: $15.70
High: $39.75

Volume

761,866 shs

Average Volume

1,130,517 shs

Market Capitalization

$1.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcus Biosciences?

The following Wall Street sell-side analysts have issued stock ratings on Arcus Biosciences in the last twelve months: Bank of America Co., Barclays PLC, Cantor Fitzgerald, Citigroup Inc., Mizuho, Morgan Stanley, SVB Leerink LLC, TheStreet, Truist Financial Co., and Wedbush.
View the latest analyst ratings for RCUS.

What is the current price target for Arcus Biosciences?

9 Wall Street analysts have set twelve-month price targets for Arcus Biosciences in the last year. Their average twelve-month price target is $41.33, suggesting a possible upside of 152.6%. Mizuho has the highest price target set, predicting RCUS will reach $51.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $33.00 for Arcus Biosciences in the next year.
View the latest price targets for RCUS.

What is the current consensus analyst rating for Arcus Biosciences?

Arcus Biosciences currently has 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RCUS will outperform the market and that investors should add to their positions of Arcus Biosciences.
View the latest ratings for RCUS.

What other companies compete with Arcus Biosciences?

Other companies that are similar to Arcus Biosciences include Summit Therapeutics, Deciphera Pharmaceuticals, Agios Pharmaceuticals, Keros Therapeutics and MoonLake Immunotherapeutics. Learn More about companies similar to Arcus Biosciences.

How do I contact Arcus Biosciences' investor relations team?

Arcus Biosciences' physical mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company's listed phone number is (510) 694-6200 and its investor relations email address is [email protected] The official website for Arcus Biosciences is www.arcusbio.com. Learn More about contacing Arcus Biosciences investor relations.